Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen. …
Percheron Therapeutics updates on Avicursen primate toxicology study
September 30, 2024 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News